Onconetix, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 201 E. FIFTH STREET, CINCINNATI, OH, 45202
Mailing Address 201 E. FIFTH STREET, CINCINNATI, OH, 45202
Phone 513-620-4101
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024 FY
$2.52M
Revenue
$21.88M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 9, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 2, 2026 | View on SEC |
| S-1/A IPO registration amendment | December 22, 2025 | View on SEC |
| 3 Initial insider ownership report | December 12, 2025 | View on SEC |
| 8-K Current report of material events | December 10, 2025 | View on SEC |
| 8-K Current report of material events | December 10, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | November 10, 2025 | View on SEC |
| S-1 IPO registration statement | November 4, 2025 | View on SEC |
Material Events
8-K Strategy Change February 9, 2026
High Impact
- Shareholders approved a reverse stock split for Onconetix, Inc.
- The primary objective is to boost the stock price above $1.00 to meet Nasdaq listing requirements and avoid delisting.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.